Global Pharmaceutical Summit 2011

eve Conference Variant Block

Dr. Guopin ZHAO
Company: Medical School of Jinan University
Title:
Topic: Combination of TCM and Western medicine and R&D of TCM dosage innovation
Introduction:
Title of Honour : ----Advanced individual as returned overseas students in Nanjing; ----"333 Project" academic, technical leader, Middle-aged experts with outstanding contributions, in Jiangsu Province; ----"Blue project" key teacher ; ----The Third-grade State Scientific and Technological Progress Prize; ----The first prize of Chinese medicine fundamental research of State ----Administration of Traditional Chinese Medicine; Research orientation: -----Clinical study of Digestive disease and cerebrovascular disease with integrative medicine; -----Ancient prescription of the treatment of intractable disease. ADIDAS ORIGINALS

Dr. Xue KE
Company: China Pharmaceutical University (CPU)
Title:
Topic:
Introduction:
Dr. X. KE, associate professor in China Pharmaceutical University (CPU). She obtained her B.S., M.S. and Ph.D. degree with a major of Pharmaceutics from CPU in China in 1994, 1997 and 2003, respectively. And at 2001, she got advanced studies at College of Pharmacy, Otago University in New Zealand. Then, she completed her Post-Doctoral Research Fellowship at School of life sciences, Nanjing University in China at 2010. Starting from Aug. 1997, she was engaged in teaching and research work in Department of Pharmaceutics in CPU. The research fields were mainly involved in studies of new pharmaceutical preparations, new dosage forms of drugs, and new drug delivery systems. She is serving as the principal investigator for several research projects including the one from National Natural Science Foundation of China (NSFC) and the two from Social Development Fund of Jiangsu Province. Also, she co-managed the awards from State Technical Platform for Drug Development, NSFC, National High Air Jordan XIV Low

Qineng PING
Company: China Pharmaceutical University (CPU)
Title:
Topic: R&D of new dosage form of pharmaceutical formulations
Introduction:
Ping Qineng，Professor of China Pharmaceutical University (CPU)，the Dean Emeritus of College of Pharmacy, the former Vice President of Pharmaceutics committee of Chinese Pharmaceutical Association and President of Pharmaceutics committee of Jiangsu Province. Prof. Ping is the editor of JPP and PDA J Pharm Sci & Tech, Acta Pharm Sinica, Chinese J New Drug, etc.. Focusing on the oral absorption of drugs and the formulation design, targeting drug delivery nanosystems, Prof. Ping takes charge of 20 projects from the State，published over 300 papers and 5 books and owned 9 New Drug Certificates of SFDA and 8 SIPO patents. He was honored by special award of the State Council, distinguishing teacher of the state, and excellent graduate supervisor of Jiangsu, the second award of teaching achievements of the State and the second award of Sci &Tech progress of Jiangsu and Hubei Province. Adidas Shoes

Huimin Sun
Company: Division of Pharmaceutical Excipients and Packaging Materials in NIFDC at SFDA
Title:
Topic: DMF regulation for pharmaceutical packaging material
Introduction:
Professor Huimin Sun is the leader of the Division of Pharmaceutical Excipients and Packaging Materials in NIFDC (National Institutes for food and drug control), the State Food and Drug Administration of China. He has served for 25 years in NIFDC. He spent 20 years on the quality control and standardization of chemical drugs and Traditional Chinese Medicine. He has drafted and reviewed lots of standards of new drugs, and substantially experienced in the quality control and standardization of drugs. In 2005，He was appointed as the leader of the Division of Pharmaceutical Excipients and Packaging Materials in NIFDC, and focused on the quality control and standardization of pharmaceutical excipients and pharmaceutical packaging materials. Under his leadership, his group has completed a national key project (No.2008BAI55B03) in China, which was a part of the National Science & Technology Pillar Program during the 11th 5-year Plan Period. This project covered the preclinicKids Footwear Online

Dr. Chunqi LI
Company: Hunter Biotechnology, Inc.
Title:
Topic: Zebrafish: A Predictive Model for Assessing Compound Toxicity, Safety and Efficacy
Introduction:

Huijun GAO
Company: Center for Drug Certification and Evaluation, SFDA
Title:
Topic: Development trends and strategies of Generics R&D
Introduction:
Vice Director, Center for Drug Certification and Evaluation, Shanghai Municipal Food and Drug Administration

Mr. Jiliang Tang
Company: Researcher at Shanghai Institute of Pharmaceutical Industry
Title:
Topic: Pharmaceutical Automation and Supervisory Control of Drug Quality
Introduction:
Member of Expert group for transformation from traditional medicine industry into electronic technology at The State Pharmaceutical Administration;Professor at International Drug Project Management Master Program in Beijing University;Procurement expert for Shanghai government;National registered plant engineering consultant;Registered national automated system engineer (ASE) Release Calendar

Dr. James Yan
Company: Hutchison MediPharma Ltd.
Title:
Topic: The current capabilities of China-based preclinical CRO for drug research and development
Introduction:
Dr. James Yan is currently the Executive Director in Hutchison MediPharma Ltd. where he is heading the Drug Safety Evaluation Department to support drug research and development process from late-stage discovery through registration. James is an American Board-certified Toxicologist and has more than 10 years of experience with a strong track record of preclinical drug safety evaluation in drug research and development. Dr. Yan received PhD degree from Peking Union Medical University and did his post-doctoral training at the Ben-May Institute for Cancer Research, University of Chicago. He started his career in industry with Pfizer and was responsible for the development of a variety of new technologies for drug safety evaluation and preclinical safety assessments. At Pfizer, he was involved in IND and NDA filings for multiple drug candidates. In 2006, James moved to Hospira, a drug development company, where he focused on toxicology programs supporting drug development and regulaadidas NMD kaufen

Standard: RMB 3,200
* BUY 3 GET 1 FREE: For four or more delegates from the same company, the fourth one will get a free entry.
* Delegate fee includes all seminar sessions, comprehensive documentation, 5-star hotel luncheons, tea breaks and cocktail party.
* Please note that hotel accommodation is NOT included in the delegate fee.